Dyspepsia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Dyspepsia, characterized by recurrent or episodic discomfort in the upper gastrointestinal tract related to eating, is associated with symptoms like heartburn, acid reflux, regurgitation, indigestion, bloating, early satiety, or weight loss. There are two primary categories of dyspepsia: functional dyspepsia, characterized by abdominal discomfort after eating, and organic dyspepsia, caused by underlying medical conditions like ulcers, gastritis, or gallbladder disease. Various factors can cause dyspepsia. Functional dyspepsia, or nonulcer dyspepsia, constitutes around 60% of cases. Approximately 15% to 25% of dyspeptic patients have gastroduodenal ulcer disease, which cannot be reliably distinguished from functional dyspepsia based on symptoms alone. Atypical gastroesophageal reflux disease accounts for 5% to 15% of cases, with other common culprits including certain medications (such as NSAIDs, Cox-2 inhibitors, Bisphosphonates, Erythromycin, Tetracyclines, Iron, Potassium supplements, Acarbose, Digitalis, and Theophylline), as well as Helicobacter pylori infection. Dyspepsia manifests through symptoms such as increased burping, excessive fullness or bloating during or after meals, and discomfort or pain in the upper abdomen or chest. Treatment options for dyspepsia typically involve dietary adjustments, H. pylori eradication, acid-reducing medications, and using prokinetic and antiemetic agents in various combinations. If left untreated, dyspepsia can progress to more severe conditions like gastroesophageal reflux disease (GERD), peptic ulcer disease, and gastritis. Long-term complications may include anemia, malnutrition, and a weakened immune system due to inadequate nutrient absorption from food.
- The prevalence of dyspepsia varies, affecting between 25% and 40% of the population, translating to approximately 77.5 million to 124 million people in the United States.
Thelansis’s “Dyspepsia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dyspepsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Dyspepsia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Dyspepsia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment